Program
KT501
A development code.
Its studies are mostly in Arthritis, Rheumatoid, led by Kali Therapeutics.
Furthest: phase 1, since Nov 13, 20251 company-led study, 1 open or runningNext primary completion: Feb 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Kali Therapeutics | 11 open or running | phase 1since Nov 13, 2025 | Nov 13, 2025 | Feb 2027phase 1 · NCT07234773 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 13, 2025First study: phase 1 study in Arthritis, RheumatoidFirst studyNCT07234773 · 24 planned · Australia
Ahead
- Feb 2027Primary completion: phase 1 study in Arthritis, RheumatoidNCT07234773
TargetBeta
“KT501 is a monoclonal antibody that depletes B cells including plasma cells by targeting CD19, BCMA and CD3.”study text, by rule · the study
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| blinatumomabrule | Amgen | phase 4 | 29 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| YK012rule | excyte-biopharma-ltd | phase 2 | 5 |
| GSK5926371 | GlaxoSmithKline | phase 2 | 2 |
| Anti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978rule | cullinan-therapeutics-inc | phase 1 | 4 |
| Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312rule | cytocares-inc | phase 1 | 4 |
| Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565 | Novartis | phase 1 | 3 |
| ATG-201rule | antengene-biologics-limited | phase 1 | 1 |
| KT502rule | Kali Therapeutics | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07234773Arthritis, Rheumatoid · Australia | 1 | Recruiting | Feb 2027 | 24 |
How it is read
Names in the registry
- “KT501”, 1 entry
Codes read as this program: KT501.
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.